Old Web
English
Sign In
Acemap
>
authorDetail
>
M. Bradley-Garelik
M. Bradley-Garelik
Imatinib
Dasatinib
Medicine
Oncology
Internal medicine
4
Papers
40
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
2011
Journal of Clinical Oncology
H. Kantarjian
Neil P. Shah
J. E. Cortes
M. Baccarani
M. Bradley-Garelik
Chao Zhu
Andreas Hochhaus
Show All
Source
Cite
Save
Citations (16)
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes.
2011
Journal of Clinical Oncology
Pierre Laneuville
M. Baccarani
J. E. Cortes
Andreas Hochhaus
H. Kantarjian
Neil P. Shah
M. Bradley-Garelik
Chao Zhu
Kimmo Porkka
Show All
Source
Cite
Save
Citations (6)
Dasatinib compared to imatinib in patients with newly diagnosedchronic-phase chronic myelogenous leukemia (CML-CP): resultsfrom the randomized phase 3 dasision tria
2010
M. Baccarani
Neil P. Shah
H. Kantarijan
Jorge E. Cortes
Sandip Shah
Manuel Ayala
Beatriz Moiraghi
Jiri Mayer
M. Bradley-Garelik
Chao Zhu
A. Hochhaus
Show All
Source
Cite
Save
Citations (1)
Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.
2010
Journal of Clinical Oncology
H. Kantarjian
Neil P. Shah
Andreas Hochhaus
J. E. Cortes
Sandip Shah
Manuel Ayala
Beatriz Moiraghi
M. Bradley-Garelik
Chao Zhu
M. Baccarani
Show All
Source
Cite
Save
Citations (17)
1